Adipotide: What It Is, Where to Get It Prescribed, and What It Costs

Adipotide is not a naturally occurring peptide and it is not a hormone. It is a peptidomimetic — a synthetic construct built to do a job the body has no equivalent for. Its full designation in the literature is CKGGRAKDC-GG-(D)(KLAKLAK)₂, and reading that string left to right tells you most of what it does.

The first segment, CKGGRAKDC, is a homing sequence: nine amino acids that bind to a particular protein on the surface of certain blood vessels. The middle, GG, is a hinge. The final segment, (D)(KLAKLAK)₂, is a pro-apoptotic motif — a short synthetic sequence that disrupts mitochondrial membranes and triggers programmed cell death in whatever cell it gets inside. On its own the killing motif is indiscriminate but cannot cross cell membranes efficiently; on its own the homing sequence does nothing but stick. Bolted together, the design is an address plus a payload.

That architecture is the single most important thing to understand about this compound. Adipotide is not a metabolic signal, an appetite drug or a hormone analogue. It is a targeting device, and every question about it — including the safety questions — is really a question about how precise the address is.

The targeting sequence was found by in vivo phage display at the University of Texas MD Anderson Cancer Center by the laboratories of Wadih Arap and Renata Pasqualini, a group whose main work is mapping the molecular "zip codes" of blood vessels in different organs. Their 2004 paper in Nature Medicine reported that CKGGRAKDC homes to the vasculature of white fat, that it binds a membrane protein called prohibitin, and that prohibitin is a marker of adipose blood vessels. Coupling it to the pro-apoptotic motif gave the construct that was later named adipotide.

"Adipotide" is a coined name, not a generic drug name. The same construct appears in the literature as prohibitin-targeting peptide-1, and in the one human study it was registered as Prohibitin-TP01. It has never had an approved brand name because it has never been an approved drug anywhere.

It is not a GLP-1 medication and shares nothing with one mechanically. It does not act on appetite centres in the brain, it does not slow gastric emptying, and it is not related to semaglutide or tirzepatide except that all three end up categorised under weight loss.

It is not a fat-burner in the metabolic sense. Nothing in the research describes it raising metabolic rate, mobilising fatty acids for oxidation, or acting on thyroid or adrenergic pathways.

And it is not a compound with human efficacy data. That point is developed below, but it belongs here too, because it is the difference between this product and most of the catalogue.

Prohibitin is a multifunctional protein found mainly on the inner mitochondrial membrane, but the 2004 Nature Medicine work reported it also appearing on the surface of endothelial cells lining the blood vessels of white adipose tissue — and, importantly, being relatively enriched there compared with the vessels of other organs. That relative enrichment is the entire basis for calling the compound "targeted". The same paper reported prohibitin expression in the vessels of human white fat, which is why the group argued the finding might translate.

The payload half is a well-characterised synthetic motif built from D-amino acids, which makes it resistant to being chewed up by proteases. Work from the same group, including a 2013 paper in PLoS One using the motif on its own against fungal cells, describes its mechanism as mitochondrial membrane depolarisation, reactive oxygen species accumulation and caspase-like activity — in plain terms, it destabilises mitochondria until the cell initiates apoptosis. It is not selective in itself. Selectivity is supposed to come entirely from where the homing sequence delivers it.

The mechanism is not that adipotide kills fat cells. It is described as killing the endothelial cells of the capillaries feeding white fat, after which the fat tissue — cut off from its supply — is resorbed. The distinction matters for expectations: this is an anti-vascular strategy borrowed from cancer research and pointed at adipose tissue, which is why the same laboratory that developed it also works on tumour vasculature.

A 2012 paper in Diabetes reported something the designers did not predict: in obese mice, the proapoptotic peptide improved glucose tolerance within two to three days, before meaningful weight change and independently of food intake, with changes in serum insulin, triglycerides, fatty acids and acylcarnitines. Microarray work in that paper described pathways of mitochondrial function and branched-chain amino acid degradation shifting back toward the pattern seen in lean animals. Whatever this compound is doing, that paper argues it is doing something to adipose tissue function and not only to adipose tissue quantity.

Prohibitin is not exclusive to fat vasculature. The proximal tubule of the kidney is a mitochondria-dense tissue with heavy reabsorptive traffic, and it is where peptide constructs of this size tend to be taken up and processed. That is the structural reason a compound designed against fat vessels produced a renal signal in primates, and it is the reason renal function is the monitoring question with this product rather than an afterthought.

The founding study, in Nature Medicine, reported that targeting the proapoptotic motif to prohibitin in the adipose vasculature caused ablation of white fat in obese mice, with resorption of established fat tissue and normalisation of metabolic measures. The authors described the effect as obesity reversal in the animals without detectable adverse effects at the doses used. This was a mouse study, and mouse fat biology is one of the areas where rodent-to-human translation has historically failed most often — a point the same group made explicitly when they moved to primates.

This is the central paper and the reason the compound is known outside its field. Published in Science Translational Medicine in 2011 by Barnhart, Christianson, Hanley and colleagues, it evaluated adipotide in spontaneously obese Old World monkeys. The reported findings were targeted apoptosis within the blood vessels of white adipose tissue, rapid weight loss and improved insulin resistance, with magnetic resonance imaging and dual-energy x-ray absorptiometry used to confirm that what was lost was white adipose tissue specifically rather than lean mass or water.

The design is stronger than most preclinical work behind compounded peptides: a spontaneously obese primate model rather than an engineered rodent, with imaging endpoints rather than scale weight alone. It is also fifteen years old, and it remains the high-water mark of the evidence.

The same paper reported, at the doses the investigators determined to be optimal, that monkeys from three different species showed changes in renal proximal tubule function. The authors characterised those changes as predictable — dose-related rather than idiosyncratic — and reversible on stopping treatment.

That sentence is worth reading carefully in both directions. It is a genuine organ-toxicity signal in the most relevant animal model available, in the tissue you would predict from the biology, and it is the reason this compound is described as experimental rather than promising. It is also not a report of irreversible kidney injury, and it was observed at deliberately dose-escalated levels in animals dosed to effect. Both halves of that are true, and a page that gives you only one of them is selling you something.

The 2012 Diabetes paper described above is the most mechanistically interesting follow-up: rapid, weight-independent improvement in glucose tolerance in obese mice. It is also a mouse study, run at doses and by routes that do not map onto a compounded vial, and its authors framed it as evidence about the role of adipose vasculature in glucose homeostasis rather than as a case for the compound as a treatment.

In 2012, Science Translational Medicine published a comment by Criscione arguing that the weight loss in the monkey study might reflect a direct effect of adipotide on food consumption rather than the vascular-ablation mechanism the authors proposed, with a reply from the original group. That exchange is part of the record and is worth knowing: the headline finding is not disputed, but the mechanism behind it was contested in the literature within months of publication and was never settled by further primate work.

There are no randomised controlled trials of adipotide in humans, and no published human efficacy data of any kind.

There was one registered human study. In December 2010, MD Anderson registered a first-in-man phase 1 trial, NCT01262664, of Prohibitin-TP01 in men who had metastatic or otherwise incurable prostate cancer and a BMI over 30. It was a dose-finding study: the stated goal was to find the highest tolerable dose, with safety as the object. The first patient was enrolled on 24 May 2012.

The trial was terminated. The registry records the reason as "terminated per PI's request", with four participants enrolled in total and a completion date of 2 January 2019. No results were posted to the registry, and no phase 1 results have been published. No phase 2 study has ever been registered. In the fourteen years since the monkey paper, the compound has not advanced.

So the honest summary of the human evidence is not "limited" or "early" — it is that there is none. Four men with advanced cancer were dosed in a study that stopped without reporting, and that is the whole of the human record.

• It does not establish that the mechanism works in humans. Prohibitin is present in human fat vasculature; whether targeting it produces the monkey result in a person has never been tested.
• It does not establish an effect size, a timeline, or a dose-response relationship in humans, because no human study reported outcomes.
• It does not establish renal safety in humans at any dose. The only organ signal in the best animal model is a renal one.
• It does not establish what happens beyond a few weeks of treatment. There is no long-term animal or human safety data.
• It does not establish efficacy for any condition as an approved treatment. It is not approved for anything, anywhere.

Nothing in the animal work suggests a person should expect to notice anything in the first several days, and the injection-site redness or mild soreness some people report says nothing about whether the compound is doing anything. This is also the window in which a physician is most likely to want a baseline picture of renal function in hand.

This is the window a single vial covers, and it is where any change in body composition would be expected to show if the animal timelines have any human analogue — which is exactly the thing nobody has measured. Anyone who tells you what you will weigh at week four is guessing, because the study that would let them say it has never been run in humans.

The animal studies were short. The primate dosing was weeks, not months, and the renal signal was dose-related. There is no long-duration data in any species. That combination is why this is prescribed, when it is prescribed at all, as a defined short course under supervision rather than as an ongoing therapy, and why the vial is sized to four weeks with one vial per fill.

No withdrawal syndrome and no rebound has been described, because nothing about stopping it has been studied in humans. In the monkey study, the renal changes were reported to resolve after treatment stopped. Whether any change in body composition would persist depends on everything that determines that in the first place — diet, activity, and whether anything about the underlying picture changed.

The directions are written in millilitres and in insulin-syringe units because that is what you can read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication, and your physician sets it.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. Injecting at a particular body site is not a way to direct the compound at fat in that area; the described mechanism is systemic delivery to a receptor that happens to be enriched in adipose vasculature everywhere.

Monday through Friday is part of the prescription, not an omission. Five days on and two off is how the course is structured, and it is also what makes 20 doses land at four weeks rather than three.

20 doses at once daily Monday through Friday is four weeks, which is why refills run on a 28-day cycle. One vial per fill, always — not a stockpile. With this compound in particular, the refill cycle is the point at which a physician reviews whether continuing is appropriate.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is printed on the label. Do not freeze it. How medication is prepared, tested and shipped is covered on quality.

The primate study reported dose-related, reversible changes in proximal tubule function in monkeys of three species. There is no human data showing whether the same thing happens in people, at what dose, or whether it would be as reversible. This is the defining safety consideration for the compound and the reason it is prescribed cautiously, in short courses, with attention to kidney function — not an incidental footnote.

The Specification above says bloodwork is not routinely required and that your physician decides. With this compound specifically, many prescribers do want a baseline picture of renal function and a check during or after a course, and hydration is usually part of the instructions. At-home blood testing covers metabolic markers without a lab visit if your physician asks for them. Anyone with known kidney disease, reduced renal function, or medications that load the kidney should raise it at intake; that row is in the table below for a reason.

Beyond the renal question, what gets reported is mostly injection-site: redness, mild soreness, occasional bruising. Some people report nausea, light-headedness or fatigue early in a course. Dehydration is worth avoiding for the same reason as above.

There is no established interaction list for adipotide, because the trials that would produce one were never completed. That is precisely why the intake asks for every medication and supplement you take, including anything that affects the kidney, and why a physician reviews it rather than a form.

Stop and contact your physician for any reaction that is severe, spreading, or involves difficulty breathing, and for any change in how much you are urinating, swelling, or unusual fatigue during a course.

These are not alternatives in any meaningful sense. Semaglutide and tirzepatide act on gut-hormone receptors to reduce appetite, are approved drugs in their branded forms, and have large randomised human trials behind them. Adipotide is an anti-vascular construct with no human efficacy data and a renal signal in primates. If the question is which one has evidence, there is no contest, and most physicians will start there.

All three are animal-evidence products categorised under weight loss, and that is where the similarity ends. AOD-9604 is a fragment of human growth hormone studied for effects on fat metabolism; 5-Amino-1MQ inhibits an enzyme inside fat cells. Both act on the biology of the fat cell. Adipotide acts on the blood vessels supplying it, and is the only one of the three whose mechanism is cytotoxic by design.

Adipotide is supplied as a vial drawn with an insulin syringe, and there is no pepti Pen cartridge for it. Pen cartridges exist for products with settled, widely prescribed dosing; a compound prescribed as a short, supervised, individually judged course is not one of them.